USPH EPS Drops 20 Percent on Miss

U.S. Physical Therapy (USPH) reported Q2 2025 GAAP EPS of $0.58, missing analyst estimates by 19.6%, and revenue missed forecasts by 11.3%, largely due to increased corporate costs from acquisition integration and system implementations. Despite these financial shortfalls, the company achieved record patient volumes and robust 22.6% revenue growth in its Industrial Injury Prevention segment. Management, while navigating persistent cost pressures and Medicare reimbursement uncertainty, raised its full-year Adjusted EBITDA guidance, increased its quarterly dividend, and authorized a new $25 million share repurchase program, signaling a strategy of balancing aggressive acquisition-driven expansion and shareholder returns against operational headwinds.

Analysis

U.S. Physical Therapy (USPH) presented a mixed Q2 2025 report, characterized by a significant top-line miss on a GAAP basis but strong underlying operational momentum and positive shareholder actions. GAAP EPS of $0.58 missed consensus by 19.6% and revenue of $168.3 million fell short by 11.3%, primarily driven by elevated corporate expenses which rose from $14.2 million to $17.5 million year-over-year due to acquisition integration and new system implementations. In contrast, Non-GAAP metrics were robust, with revenue growing 18.0% to $197.3 million and Non-GAAP EPS rising 11.0% to $0.81, beating estimates. The core growth driver was inorganic expansion, reflected in a 16.7% increase in total patient visits and the launch of a new home-care service. The Industrial Injury Prevention (IIP) segment was a standout performer, with revenue climbing 22.6% and gross margin expanding to 22.0%. However, a critical point of concern is the near-stagnant organic growth, with revenue from mature clinics increasing by only 0.2%. Management signaled confidence by raising full-year Adjusted EBITDA guidance, increasing the quarterly dividend to $0.45 per share, and authorizing a new $25 million share repurchase program, though this aggressive capital deployment has sharply reduced cash reserves to $34.1 million from $112.9 million a year prior.

Key Decisions for Investors

• Investors should prioritize non-GAAP metrics like Adjusted EBITDA and operational KPIs such as patient volumes, as the significant GAAP earnings miss appears driven by temporary acquisition-related costs, a view supported by management's raised full-year EBITDA guidance.
• The near-zero 0.2% organic growth in mature clinics warrants close scrutiny, indicating a heavy reliance on an M&A strategy that has significantly depleted cash reserves and increased integration risk.
• While the increased dividend and new buyback program are positive signals of management confidence, these should be weighed against persistent headwinds from Medicare reimbursement cuts and rising corporate costs that are expected to continue through 2026.